INO INOVIO PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1055726 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.0%
TTM net income YoY20.8%
TTM EPS YoY54.2%
Revenue 3-yr CAGR-81.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-132,871.3%
Net margin-130,000.0%
FCF margin-136,074.5%
EBITDA margin-130,701.4%
Returns
ROE-183.5%
ROA-90.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio3.9%
Payout ratio—
Capex / revenue437.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $65,343 | $217,756 | $832,010 | $10.26M | $1.77M |
| R&D expense | $54.21M | $75.62M | $86.68M | $187.65M | $249.24M |
| SG&A expense | $32.68M | $37.00M | $47.58M | $90.19M | $53.75M |
| Operating income | -$86.82M | -$112.40M | -$143.94M | -$267.57M | -$301.22M |
| Interest expense | $0 | $177,833 | $1.22M | $1.25M | $1.94M |
| Pretax income | -$84.95M | -$107.25M | -$135.12M | -$277.65M | -$303.22M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$84.95M | -$107.25M | -$135.12M | -$279.82M | -$303.66M |
| EBITDA | -$85.40M | -$110.65M | -$141.32M | -$263.92M | -$298.18M |
| EPS (basic) | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| EPS (diluted) | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 |
| Weighted avg. shares (diluted) | 46.89M | 27.16M | 22.17M | 19.89M | 17.40M |
| Balance sheet | |||||
| Cash & equivalents | $44.27M | $65.81M | $14.31M | $46.33M | $71.14M |
| Short-term investments | $14.24M | $28.30M | $130.98M | $206.67M | $330.17M |
| Receivables | $450 | $1.20M | $2.41M | $1.70M | $5.47M |
| Current assets | $61.12M | $97.83M | $153.11M | $315.24M | $448.44M |
| PP&E, net | $2.53M | $3.66M | $4.96M | $7.73M | $17.45M |
| Goodwill | — | — | $0 | $10.51M | $10.51M |
| Intangibles | — | — | $0 | $2.13M | $2.63M |
| Total assets | $74.31M | $113.20M | $170.95M | $348.53M | $495.94M |
| Current liabilities | $43.67M | $35.33M | $42.57M | $96.87M | $65.74M |
| Total liabilities | $50.21M | $44.69M | $53.60M | $126.17M | $96.27M |
| Shareholders' equity | $24.10M | $68.50M | $117.35M | $222.36M | $399.67M |
| Shares outstanding | 69.00M | 36.10M | 22.79M | 21.09M | 217.38M |
| Cash flow statement | |||||
| Operating cash flow | -$88.63M | -$104.08M | -$124.37M | -$216.22M | -$215.71M |
| Capital expenditure | $285,698 | $487,832 | $320,898 | $969,153 | $1.23M |
| Free cash flow | -$88.92M | -$104.56M | -$124.69M | -$217.18M | -$216.94M |
| Investing cash flow | $14.04M | $104.07M | $87.36M | $109.59M | -$175.34M |
| Financing cash flow | $53.05M | $51.48M | $5.00M | $81.84M | $211.50M |
| Depreciation & amortization | $1.42M | $1.75M | $2.62M | $3.66M | $3.04M |
| Stock-based compensation | $3.76M | $6.60M | $11.07M | $22.56M | $26.34M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.